Literature DB >> 17315493

[Severe phenytoin intoxication in patients with hypoalbuminaemia].

E M Kemper1, H J M van Kan, P Speelman, K de Gans, J H Beijnen, J H M Schellens.   

Abstract

Two patients, a 35-year-old woman and a 60-year-old man, developed severe neurological side effects during treatment with phenytoin: disorientation, myoclonia, hallucinations and drowsiness in the first patient and a comatose state in the second. The woman had spina bifida, a ventriculoperitoneal drain because of hydrocephalus, recurrent urinary-tract infection, and a history of status epilepticus. The man suffered from diabetic ketoacidosis complicated by epileptic convulsions. In both patients, the total phenytoin concentration in the blood was within the therapeutic range of 8-20 mg/l. However, both had low serum albumin concentrations, below 25 g/l. Low serum albumin levels are associated with increased concentrations of the free fraction of phenytoin. Toxic levels of free phenytoin were found: 4 and 8 mg/l, respectively, while the therapeutic range is 0.5-2 mg/l. The first patient recovered after treatment with phenytoin was stopped, after which she was placed on a lower dosage; the second patient died. When prescribing phenytoin to patients with hypoalbuminaemia, one should be aware of the risk of intoxication due to a high level of free phenytoin and consequently an increased risk of severe neurological side effects.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17315493

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  2 in total

1.  Impact of hypoalbuminemia on voriconazole pharmacokinetics in critically ill adult patients.

Authors:  Kim Vanstraelen; Joost Wauters; Ine Vercammen; Henriette de Loor; Johan Maertens; Katrien Lagrou; Pieter Annaert; Isabel Spriet
Journal:  Antimicrob Agents Chemother       Date:  2014-09-02       Impact factor: 5.191

2.  A Novel Correction Equation Avoids High-Magnitude Errors in Interpreting Therapeutic Drug Monitoring of Phenytoin Among Critically Ill Patients.

Authors:  Megan E Barra; Kristy M Phillips; David Y Chung; Eric S Rosenthal
Journal:  Ther Drug Monit       Date:  2020-08       Impact factor: 3.118

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.